HRP20250207T1 - Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona - Google Patents

Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona Download PDF

Info

Publication number
HRP20250207T1
HRP20250207T1 HRP20250207TT HRP20250207T HRP20250207T1 HR P20250207 T1 HRP20250207 T1 HR P20250207T1 HR P20250207T T HRP20250207T T HR P20250207TT HR P20250207 T HRP20250207 T HR P20250207T HR P20250207 T1 HRP20250207 T1 HR P20250207T1
Authority
HR
Croatia
Prior art keywords
compound
use according
cancer
imipridone
gpcr
Prior art date
Application number
HRP20250207TT
Other languages
English (en)
Croatian (hr)
Inventor
Joshua E. Allen
Martin Stogniew
Varun Vijay PRABHU
Original Assignee
Oncoceutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/015817 external-priority patent/WO2016123571A1/en
Application filed by Oncoceutics, Inc. filed Critical Oncoceutics, Inc.
Publication of HRP20250207T1 publication Critical patent/HRP20250207T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
HRP20250207TT 2016-01-29 2017-01-30 Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona HRP20250207T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2016/015817 WO2016123571A1 (en) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
US201662308325P 2016-03-15 2016-03-15
US201662425403P 2016-11-22 2016-11-22
EP17745078.0A EP3408298B1 (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones
PCT/US2017/015608 WO2017132661A2 (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones

Publications (1)

Publication Number Publication Date
HRP20250207T1 true HRP20250207T1 (hr) 2025-04-11

Family

ID=59398848

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20250207TT HRP20250207T1 (hr) 2016-01-29 2017-01-30 Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona

Country Status (25)

Country Link
US (2) US11116771B2 (enExample)
EP (2) EP4524567A3 (enExample)
JP (2) JP7030701B2 (enExample)
KR (2) KR20250065717A (enExample)
CN (2) CN115844895B (enExample)
AU (2) AU2017211423B2 (enExample)
BR (1) BR112018015590A2 (enExample)
CA (1) CA3013044A1 (enExample)
DK (1) DK3408298T3 (enExample)
ES (1) ES3012491T3 (enExample)
FI (1) FI3408298T3 (enExample)
HR (1) HRP20250207T1 (enExample)
HU (1) HUE070208T2 (enExample)
IL (3) IL316540A (enExample)
LT (1) LT3408298T (enExample)
MA (1) MA43879B1 (enExample)
MX (2) MX2018009227A (enExample)
NZ (1) NZ745425A (enExample)
PL (1) PL3408298T3 (enExample)
PT (1) PT3408298T (enExample)
RS (1) RS66519B1 (enExample)
SG (2) SG10202108306UA (enExample)
SI (1) SI3408298T1 (enExample)
SM (1) SMT202500086T1 (enExample)
WO (1) WO2017132661A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015590A2 (pt) * 2016-01-29 2019-10-01 Oncoceutics Inc modulação de receptor acoplado à proteína g (gpcr) por imipridonas
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
EP3682035B1 (en) * 2017-09-15 2025-02-05 The Regents of the University of California Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring
WO2019067709A1 (en) * 2017-09-27 2019-04-04 The Regents Of The University Of California GPCR IN FIBROBLASTS ASSOCIATED WITH CANCER
WO2019152733A1 (en) 2018-01-31 2019-08-08 Mayo Foundation For Medical Education And Research Methods of treating fibrotic pathologies
CA3096448A1 (en) * 2018-04-09 2019-10-17 Orgenesis Inc. Bioxomes particles, redoxomes, method and composition
CN109157656B (zh) * 2018-10-15 2021-08-27 重庆医科大学附属永川医院 一种双靶标肿瘤疫苗及其制备方法和应用
JP2022520997A (ja) * 2019-02-22 2022-04-04 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム イミプリドンを使用する方法
KR20220041847A (ko) 2019-07-30 2022-04-01 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 섬유성 병리를 치료하기 위한 화합물 및 방법
KR102403686B1 (ko) 2020-05-15 2022-05-31 뉴로핏 주식회사 뇌자극 위치 제공장치 및 방법
WO2022029459A1 (en) 2020-08-06 2022-02-10 Eötvös Loránd Tudományegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
CN112402439A (zh) * 2020-11-18 2021-02-26 西安组织工程与再生医学研究所 miR-325核酸类似物在制备改善肝胶原沉积相关产品中的应用
US11648248B1 (en) 2022-01-12 2023-05-16 King Abdulaziz University Potent antimicrobial compounds with a pyridazine nucleus
CN119384515A (zh) * 2022-08-03 2025-01-28 施显东 基于drd1和/或drd5的精神状态定量测定方法及其应用
CN115531378B (zh) * 2022-10-19 2023-10-13 中国医学科学院医药生物技术研究所 Pht427作为ndm-1与kpc-2双重抑制剂的应用
WO2024157207A1 (en) * 2023-01-25 2024-08-02 Gpcr Therapeutics, Inc. Gpcr inhibitors and uses thereof
WO2024218275A1 (en) * 2023-04-20 2024-10-24 Institut Gustave Roussy Liquid and solid compositions of imipridone derivatives
CN116731136B (zh) * 2023-08-04 2023-12-05 齐鲁工业大学(山东省科学院) H3k23a组蛋白点突变在提高酿酒酵母乙酸耐受性及木糖发酵性能中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004082570A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
EP1644536A4 (en) 2003-07-08 2008-07-23 Univ California GENETIC MARKERS FOR RESPONSE TO ATYPIC ANTIPSYCHOTICS AND ANTIDEPRESSIVA AND METHOD FOR USE THEREOF
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
EP2197340A4 (en) 2007-09-19 2015-10-21 Oncofluor Inc METHOD OF IMAGING AND PROCESSING ORGANS AND TISSUES
EP2680853A4 (en) * 2011-02-28 2014-08-06 Univ Mcmaster TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS
RS65813B1 (sr) 2011-04-29 2024-08-30 Penn State Res Found Indukcija malog molekula trail genom u normalnim i tumorskim ćelijama kao antikancerska terapija
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
ES2734568T3 (es) 2013-03-13 2019-12-10 Oncoceutics Inc 7-Bencil-10-(2-metilbencil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3H)-ona para su uso en el tratamiento de cáncer
CN106163524B (zh) 2013-11-15 2019-11-08 昂克希尔迪克斯有限公司 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法
EP3662910B1 (en) * 2014-03-31 2024-09-18 The Scripps Research Institute Pharmacophore for trail induction
JP6802172B2 (ja) * 2015-01-30 2020-12-16 オンコシューティクス インコーポレイテッドＯｎｃｏｃｅｕｔｉｃｓ，Ｉｎｃ． ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法
CN104860948B (zh) * 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
BR112018015590A2 (pt) * 2016-01-29 2019-10-01 Oncoceutics Inc modulação de receptor acoplado à proteína g (gpcr) por imipridonas
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Also Published As

Publication number Publication date
WO2017132661A3 (en) 2017-08-31
US11116771B2 (en) 2021-09-14
NZ784773A (en) 2025-05-02
AU2017211423B2 (en) 2021-10-28
AU2022200583A1 (en) 2022-02-24
JP2022046528A (ja) 2022-03-23
AU2017211423A1 (en) 2018-09-06
IL316540A (en) 2024-12-01
US20190307751A1 (en) 2019-10-10
CA3013044A1 (en) 2017-08-03
HUE070208T2 (hu) 2025-05-28
MX2018009227A (es) 2018-11-09
CN115844895A (zh) 2023-03-28
EP3408298A2 (en) 2018-12-05
SMT202500086T1 (it) 2025-03-12
IL286923A (en) 2021-10-31
ES3012491T3 (en) 2025-04-09
JP2019511460A (ja) 2019-04-25
IL260815B (en) 2021-10-31
JP7030701B2 (ja) 2022-03-07
FI3408298T3 (fi) 2025-02-24
SI3408298T1 (sl) 2025-05-30
IL286923B1 (en) 2024-12-01
CN109311980B (zh) 2023-01-17
LT3408298T (lt) 2025-03-10
MA43879A (fr) 2018-12-05
KR20180125460A (ko) 2018-11-23
PT3408298T (pt) 2025-03-20
EP3408298B1 (en) 2024-11-20
MA43879B1 (fr) 2025-02-28
PL3408298T3 (pl) 2025-03-31
AU2022200583B2 (en) 2024-05-02
MX2023004443A (es) 2023-05-08
SG10202108306UA (en) 2021-08-30
CN109311980A (zh) 2019-02-05
KR102801670B1 (ko) 2025-04-25
US20220072001A1 (en) 2022-03-10
EP4524567A2 (en) 2025-03-19
CN115844895B (zh) 2025-10-17
BR112018015590A2 (pt) 2019-10-01
EP4524567A3 (en) 2025-07-23
NZ745425A (en) 2023-03-31
DK3408298T3 (en) 2025-03-03
EP3408298A4 (en) 2019-09-04
WO2017132661A2 (en) 2017-08-03
SG11201806401YA (en) 2018-08-30
RS66519B1 (sr) 2025-03-31
IL286923B2 (en) 2025-04-01
KR20250065717A (ko) 2025-05-13

Similar Documents

Publication Publication Date Title
HRP20250207T1 (hr) Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona
SG11201912154XA (en) Aadc polynucleotides for the treatment of parkinson's disease
EP2968071A4 (en) DEVICE FOR THE ORAL RELEASE OF THERAPEUTIC COMPOUNDS
IL251787B (en) Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
UA118759C2 (uk) Сполуки 3,4-дигідроізохінолін-2(1н)-ілу
MA52906A (fr) Procédé de préparation d'amg 416
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
FR3054331B1 (fr) Systeme de generation d'impulsions lumineuses breves ou ultra-breves
PT2994160T (pt) Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
WO2015100092A3 (en) 7-beta analogs of orvinols
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
EP2973821A4 (en) PREPARATION OF AN ADVANCED CCMS FOR AMFCS BY AMINIZATION AND NETWORKING OF THE PRE-FORMAT FORM OF IONOMERS
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
EA201691413A1 (ru) Селективные антагонисты nr2b
EP3362578A4 (en) PROCEDURE FOR GENOMIC ASSESSMENT AT VIEH
MX2018005756A (es) Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.
HUE051458T2 (hu) 2,3-Dihidro-1H-indén-1-on-származékok retinsavval rokon gazdag receptor gamma (ror gamma) antagonistákként szklerózis multiplex kezelésére
MX2022005024A (es) Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).
SG11202005822PA (en) Therapeutic agent for nervous system disease
EP3645548A4 (en) METHOD FOR PRODUCING BALIC ACIDS
EP3377111A4 (en) AMINO DRUGS OF PHARMACEUTICAL COMPOUNDS
EP3456729A4 (en) CRYSTALLINE POLYMORPH OF 15-HYDROXY-OSATERONACETATE
WO2014014794A3 (en) Mineralocorticoid receptor antagonists